InflaRx N.V.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Non-accelerated filer
State of Incorporation
Netherlands
Business Address
WINZERLAER STR. 2, JENA, 2M, 07745
Mailing Address
WINZERLAER STR. 2, JENA, 2M, 07745
Phone
49 3641 508180
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | April 9, 2026 | View on SEC |
| 6-K Foreign company current report | April 2, 2026 | View on SEC |
| 20-F Foreign company annual report | March 20, 2026 | View on SEC |
| 6-K Foreign company current report | March 19, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
Annual Reports
20-F
March 20, 2026
- Advancing multiple promising drug candidates (vilobelimab, izicopan) with key clinical trial milestones expected in 2026.
- Preparing for regulatory submissions (BLA to FDA, MAA to EMA) for GOHIBIC (vilobelimab) for ARDS in 2026.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.